State-Owned Pharma Group On Horizon As Korea Eyes Secure Supplies
Executive Summary
South Korea is mulling setting up a state-owned pharma firm as lawmakers, government officials and experts reach consensus during a recent public hearing that official intervention and control could help stabilize drug supplies and promptly deal with public health and other emergency situations.
You may also be interested in...
Korea Signals Continued Policy Support For Pharma In 2018
Despite the regime change, South Korea remained generally supportive of the pharma and biotech industry in 2017. With comprehensive long-term plans proposed to nurture these sectors, the government appears poised to pursue its favorable stance towards industry in the coming year.
Korea Lays Essential Drug Plans Amid Ongoing Supply Concerns
South Korea unveils measures to stabilize supply of essential drugs – including a list of the drugs to monitor, stockpile and manage – to deal with public health crises in time and guarantee treatment opportunities for the nation.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.